Alfuzosin: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett No edit summary |
mNo edit summary |
||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 4: | Line 4: | ||
==History== | ==History== | ||
Uroxatral brand of alfuzosin was approved by the [[Food and Drug Administration]] in the [[United States]] with a [http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/NewDrugApplicationNDA/ New Drug Application] (NDA) in 2003.<ref>[http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchType=BasicSearch&Search_Button=Submit&searchTerm=021287 Drugs@FDA]. U S Food and Drug Administration</ref> A generic version was approved with a [http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ Abbreviated New Drug Application] (ANDA) in 2009.<ref>[http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchType=BasicSearch&Search_Button=Submit&searchTerm=079013 Drugs@FDA]. U S Food and Drug Administration</ref> | Uroxatral brand of alfuzosin was approved by the [[Food and Drug Administration]] in the [[United States of America]] with a [http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/NewDrugApplicationNDA/ New Drug Application] (NDA) in 2003.<ref>[http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchType=BasicSearch&Search_Button=Submit&searchTerm=021287 Drugs@FDA]. U S Food and Drug Administration</ref> A generic version was approved with a [http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ Abbreviated New Drug Application] (ANDA) in 2009.<ref>[http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchType=BasicSearch&Search_Button=Submit&searchTerm=079013 Drugs@FDA]. U S Food and Drug Administration</ref> | ||
<!-- | |||
==Pharmacology== | ==Pharmacology== | ||
===Administration=== | ===Administration=== | ||
| Line 12: | Line 13: | ||
===Excretion=== | ===Excretion=== | ||
===Toxicity=== | ===Toxicity=== | ||
--> | |||
==External links== | ==External links== | ||
| Line 17: | Line 19: | ||
==References== | ==References== | ||
<references/> | <references/>[[Category:Suggestion Bot Tag]] | ||
Latest revision as of 11:01, 8 July 2024
In medicine, alfuzosin is a selective antagonist of alpha1-adrenergic receptors.
History
Uroxatral brand of alfuzosin was approved by the Food and Drug Administration in the United States of America with a New Drug Application (NDA) in 2003.[1] A generic version was approved with a Abbreviated New Drug Application (ANDA) in 2009.[2]
External links
The most up-to-date information about Alfuzosin and other drugs can be found at the following sites.
- Alfuzosin - FDA approved drug information (drug label) from DailyMed (U.S. National Library of Medicine).
- Alfuzosin - Drug information for consumers from MedlinePlus (U.S. National Library of Medicine).
- Alfuzosin - Detailed information from DrugBank.